Apertor Pharmaceuticals

Apertor creates novel molecular glues for therapeutic applications in multiple disease areas. The company applies a world-class synthetic biology platform using non-model organisms, a deep knowledge of complex natural products relevant to human health, and a computational pipeline enabled by structure-guided design. The result is a first-in-class approach to solving important pharmacological problems and delivering new, high-value treatment options for patients. The company was co-founded by UC Berkeley Professor of Chemical & Biomolecular Engineering and of Bioengineering Jay Keasling.

Formerly known as Apertor Labs.